Clinical Pharmacology & Therapeutics

TABLE I

FROM:

Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam

Jamila A. Perini and Guilherme Suarez-Kurtz

BACK TO ARTICLE

Table I. CYP2C9 genotypes and piroxicam pharmacokinetic and pharmacodynamic parameters

Figure and tables index
 CYP2C9 genotype
 *1/*1 (n = 17) [mean plusminus SD (range)]*1/*3 (n = 9) [mean plusminus SD (range)]*3/*3 (n = 1)
Pharmacokinetic parameter   
 Cmax (mug/mL)2.5 plusminus 0.7 (1.2-3.6)2.4 plusminus 0.4 (1.9-3.2)2.5
 AUC0-infinity (mug dot mL-1 dot h)154 plusminus 37 (101-237)259 plusminus 95 (163-442)817
 t½ (h)48 plusminus 9 (38-65)80 plusminus 24 (51-138)420
 CL/Fcor (mL dot h-1 dot kg-1)2.0 plusminus 0.5 (1.1-2.9)1.3 plusminus 0.4 (0.7-1.9)0.3
Pharmacodynamic parameter   
 TxB2 Cmin (% of baseline)10.6 plusminus 8.6 (0.04-23.0)3.0 plusminus 2.3 (0.5-6.0)0.8
 TxB2 AUC (% of baseline dot h)10,190 plusminus 2632 (6669-15,097)18,241 plusminus 2397 (5014-21,000)200,500
 PGE2 Cmin (% of baseline)27.3 plusminus 20.8 (4.0-65.0)32.4 plusminus 13.3 (19.0-56.0)4.8
 PGE2 AUC (% of baseline dot h)7772 plusminus 5213 (1000-15,890)10,498 plusminus 2581 (7830-14,796)64,900

 Cmax, Peak concentration; AUC0-infinity, area under plasma concentration–time curve from time 0 to infinity; t½, elimination half-life; CL/Fcor, oral clearance/bioavailability corrected for body weight; TxB2, thromboxane B2; Cmin, minimal serum concentration; AUC, area above effect-time curve; PGE2, prostaglandin E2.

Figure and tables index
BACK TO ARTICLE